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Introduction
As the sentinel antigen-presenting cells (APCs) of the immune sys-
tem, DCs play a central role in initiating antigen-specific immu-
nity and tolerance (1). In cancer, DCs act as the initial link between 
oncogenesis and the host immune system, the first step of a can-
cer/immunity cycle that aims to eliminate cancer cells through the 
activation of T cells (2). Tumor-proximal DCs can capture neoan-
tigens created and released during oncogenesis, which the DCs 
subsequently process and present to cognate T cells to generate 
antitumor T cell responses. However, such T cell responses can 
only be generated if certain additional conditions are met in the 
local environment (2). These conditions consist of locally pres-
ent immunogenic signals, such as proinflammatory cytokines, 
danger-associated molecular patterns (DAMPs), or pathogen- 
associated molecular patterns (PAMPs). Such signals trigger DCs 
to present captured tumor-associated antigens (TAAs) via MHC 
class I (MHC-I) and MHC-II molecules to T cells in cooperation 
with costimulatory molecules such as CD80 and CD86, resulting 
in the priming and activation of TAA-specific effector T cells.
Therapies harnessing these properties of DCs to generate 
immune responses against tumors have great potential, though 
clinical progress of this application remains in its infancy. One nota-
ble exception is the success of the immunotherapy sipuleucel-T 
for early-stage, hormone-refractory prostate cancer. Sipuleucel-T 
is composed of autologous peripheral blood mononuclear cells 
(PBMCs) including APCs (such as DCs and their precursors) that 
have been stimulated ex vivo with a fusion protein consisting of 
the cytokine granulocyte macrophage colony-stimulating factor 
(GM-CSF), which drives DC differentiation and activation, com-
bined with a prostate antigen (3). Nonetheless, DC-based immuno-
therapy is challenging to practice in clinical settings. Implementing 
such therapies across large populations is costly, requires dedicated 
expertise, and requires monitoring of well-defined quality control 
parameters. Furthermore, it is difficult to store DCs over long peri-
ods of time while maintaining their efficacy (4).
The use of DC-derived exosomes (Dex) has been heralded 
as a solution to many of the technical challenges associated with 
DC-based immunotherapy (see Table 1) because they maintain 
the essential immunostimulatory faculties of DCs (e.g., sharing 
the ability to present antigens to T cells), while the stable nature 
of exosomal membranes allows their frozen storage for at least 
6 months (5). As biologics, Dex are also more amenable to a strictly 
regulated and monitored manufacturing process (e.g., their com-
position and MHC-I and MHC-II content can be easily defined), 
and they lack the risks associated with viable cellular or viral ther-
apies such as the risk of in vivo replication (6). Finally, treatment 
with cell-free Dex may be more resistant to immunomodulatory 
events that occur in tumors than other anticancer vaccines; such 
events can downregulate costimulatory molecules on DCs and 
impede stimulation of T cell responses (7).
As discussed in detail in other sections of this review series, 
DCs are one of the many cell types able to secrete membrane ves-
icles, such as exosomes, into the extracellular environment. This 
manner of signaling can modulate recipient cells, such as immune 
cells or cancer cells, to a level beyond classical ligand/receptor 
signaling pathways and can create complex cellular modifica-
tions that may play a substantial role in how tumor development 
or immune responses proceed. Moreover, detection of circulating, 
cancer cell–derived exosomes can serve as a noninvasive diagnos-
tic and screening tool to detect early stages of cancer, facilitating 
DC-derived exosomes (Dex) are nanometer-sized membrane vesicles that are secreted by the sentinel antigen-presenting 
cells of the immune system: DCs. Like DCs, the molecular composition of Dex includes surface expression of functional 
MHC-peptide complexes, costimulatory molecules, and other components that interact with immune cells. Dex have the 
potential to facilitate immune cell–dependent tumor rejection and have distinct advantages over cell-based immunotherapies 
involving DCs. Accordingly, Dex-based phase I and II clinical trials have been conducted in advanced malignancies, showing 
the feasibility and safety of the approach, as well as the propensity of these nanovesicles to mediate T and NK cell–based 
immune responses in patients. This Review will evaluate the interactions of Dex with immune cells, their clinical progress, and 
the future of Dex immunotherapy for cancer.
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